Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
DUBLIN, Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today announced that the Company has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) ... Biopharmaceuticals, Generics, Gastroenterology, FDAAllergan, Valeant Pharmaceuticals, IFAXAN, rifaximin, irritable bowel syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 29, 2016 Category: Pharmaceuticals Source Type: news
Electronic program reduces cirrhosis readmission rates
An electronic quality improvement initiative for patients with cirrhosis has achieved significant reductions in 30-day readmission rates.
The program’s goals included universal use of rifaximin and... (Source: Family Practice News)
Source: Family Practice News - February 25, 2016 Category: Primary Care Source Type: news
Liver Cirrhosis Treatment May Curb Cerebral EdemaLiver Cirrhosis Treatment May Curb Cerebral Edema
Lactulose and rifaximin treatment of cirrhosis patients with minimal hepatic encephalopathy (MHE) reverses low-grade cerebral edema, according to researchers from India. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 29, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Monthly News Roundup - May 2015
Viberzi and Xifaxan FDA-Approved For Diarrhea-Predominant IBS
Irritable bowel syndrome with diarrhea (IBS-D) may affect up to 15 million Americans, especially women, and treatment options are limited. In response, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 31, 2015 Category: Pharmaceuticals Source Type: news
Rifaximin for IBS: Where Do We Stand?Rifaximin for IBS: Where Do We Stand?
Dr David Johnson reviews the latest data on rifaximin treatment for diarrhea-predominant irritable bowel syndrome. Medscape Gastroenterology (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 29, 2015 Category: Drugs & Pharmacology Tags: Gastroenterology Commentary Source Type: news
FDA Approves Two New Treatments for Diarrhea-Predominant IBS (FREE)
By Kristin J. Kelley
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
Eluxadoline (Viberzi) and rifaximin (Xifaxan) have both been approved to treat irritable bowel syndrome with diarrhea. The approvals … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 29, 2015 Category: Primary Care Source Type: news
After Salix acquisition, Valeant receives FDA approval for IBS-D drug
Shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) traded up about 1.5 percent after markets closed Wednesday on news that the U.S. Food and Drug Administration approved the drug Xifaxan to treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Quebec's Valeant acquired Xifaxan when it bought Raleigh’s Salix Pharmaceuticals for $11 billion, or $173 per share in cash, in April. Already, Xifaxan was Salix’s biggest seller, but the new indication could drive… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news
FDA OKs Eluxadoline and Rifaximin for IBS With DiarrheaFDA OKs Eluxadoline and Rifaximin for IBS With Diarrhea
The drugs from two separate companies relieve pain and improve stool consistency for patients with IBS along with diarrhea. FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2015 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
After Salix acquisition, Valeant receives FDA approval for IBS-D drug
Shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) traded up about 1.5 percent after markets closed Wednesday on news that the U.S. Food and Drug Administration approved the drug Xifaxan to treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Quebec's Valeant acquired Xifaxan when it bought Raleigh’s Salix Pharmaceuticals for $11 billion, or $173 per share in cash, in April. Already, Xifaxan was Salix’s biggest seller, but the new indication could drive… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - May 27, 2015 Category: Hospital Management Authors: Jason deBruyn Source Type: news
FDA approves two therapies to treat IBS-D
The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 27, 2015 Category: American Health Source Type: news
FDA Approves Two Therapies to Treat Irritable Bowel Syndrome with Diarrhea (IBS-D)
May 27, 2015 -- The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2015 Category: Pharmaceuticals Source Type: news
Lupin launches anti-bacterial Zaxine tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with HE, a complication of liver disease (cirrhosis). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 20, 2015 Category: Pharmaceuticals Source Type: news
Treating the Root Cause of IBS: Small Intestine Bacterial Overgrowth
Rosie is a 30-year-old banker with very long work hours who came to see me with symptoms of gas, bloating and constipation. She had stomach cramps after eating, stubborn acne and a weight gain of 10 pounds in the last couple years despite a good diet and exercising regularly. A visit to a gastroenterologist had yielded the diagnosis of irritable bowel syndrome (IBS) after testing that included an endoscopy, a colonoscopy, blood work, and an MRI -- all of which were essentially normal. Rosie's doctor prescribed Amitiza, a drug typically given for constipation, which caused her nausea and abdominal pain. She stopped taking i...
Source: Healthy Living - The Huffington Post - April 1, 2015 Category: Consumer Health News Source Type: news
Bidding war for Salix shows confidence in its lead drug
The bidding war for Raleigh's Salix Pharmaceuticals (Nasdaq: SLXP) shows that Valeant (NYSE: VRX) has high confidence that Salix will receive a secondary approval for its biggest selling drug Xifaxan.
Specifically, Salix applied with the U.S. Food and Drug Administration to sell Xifaxan as a treatment for irritable bowel syndrome with diarrhea, or IBS-D, something analysts predict will significantly increase revenue.
Indeed, it is this indication for this drug that has made Salix become such an… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 16, 2015 Category: Pharmaceuticals Authors: Jason deBruyn Source Type: news
Rifaximin gets the OK from NICE for hepatic encephalopathy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news
